logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Evaluating Regenxbio Clinical Performance of RGX-314 Using the Navxpress™ Manufacturing Platform Process

Prohost's Beliefs About the Status of the Market That the market is still volatile and Bear. Investors in the biotech sector who intend to bet on clinical stage firms must restrict their choices to companies that already have proof of...

Read More

February 13, 2023

0

Apellis Pharmaceuticals: A Biopharmaceutical Firm That We Like

Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. ( APLS ) is a biopharma firm developing novel products for debilitating and life-threatening diseases. Currently, Apellis has two approved medicines targeting C3. These drugs include the first and only approved therapy for geographic atrophy,...

Read More

February 23, 2023

0

What We Are Looking for in a Bear Market

The Stock Market The volatility continues in the Bear market with investors not knowing what to do with such instability. Professional traders and robots are all puzzled. Friday, March 10, 2023 the market started the trading day by dropping 150...

Read More

March 11, 2023

0

CymaBay Therapeutics' Clinical Trials Brought Proof of Concept of its Technology and More

CymaBay Therapeutics CymaBay Therapeutics ( CBAY ) is a clinical-stage biopharmaceutical firm focused on improving the lives of people with liver and other chronic diseases that have a high unmet medical need through a pipeline of innovative therapies.   The firm...

Read More

March 21, 2023

0

Vertex Pharmaceuticals Recent Impacting News

Important News from Vertex Vertex Pharmaceuticals ( VRTX ) is a worldwide biotechnology company that invests in scientific innovation. The firm created transformative medicines for people with serious diseases. Vertex has multiple approved medicines that treat the underlying cause of...

Read More

March 24, 2023

0

An Important New Licensing Agreement Between Vertex Pharmaceuticals and CRISPR Therapeutics

Vertex Pharmaceuticals and Crispr Therapeutics Agreement Aims at Accelerating Vertex's Hypo immune Cell Therapies for Type 1 Diabetes Vertex Pharmaceuticals (VRTX) and  CRISPR Therapeutics ( CRSP ) announced that they have entered into a new non-exclusive licensing agreement for the use of...

Read More

March 27, 2023

0

TG Therapeutics Announced Positive CHMP Opinion of BRIUMVI for Relapsing Forms of MS in Adults

TG Therapeutics Positive CHMP of BRIUMVI TG Therapeutics, Inc. ( TGTX ) , informed that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has recommended the approval of BRIUMVI™...

Read More

April 3, 2023

0

Sanofi to Reach Full Commercial Control of the Antibody Beyfortus (nirsevimab) against RSV in the U.S.

Sanofi Commercial Control of Beyfortus Against RSV In the morning, we promised to tell our readers how AstraZeneca's ( AZN ) , Sobi, and Sanofi ( SNY ) simplified their contractual arrangements that enabled Sanofi to reach a full commercial...

Read More

April 12, 2023

0

Innoviva: The FDA Advisory Committee Unanimously Recommended Approval of Sulbactam-Durlobactam

News from Innoviva That We Consider Positively Impacting and Extremely Important Innoviva, Inc. ( INVA ) (Innoviva) , announced that the FDA Antmicrobial Drugs Advisory Committee ( AMDAC ) has unanimously voted 12-0 in favor of approval of sulbactam-durlobactam based...

Read More

April 19, 2023

0

Atea Pharmaceuticals: The U.S. FDA Granted Fast Track Designation to Bemnifosbuvir Oral Antiviral for COVID-19

Atea Pharmaceuticals Receives Fast Track Designation for Bemnifosbuvir Atea Pharmaceuticals ( AVIR ) announced that the U.S. FDA has granted Fast Track designation to its product bemnifosbuvir for the treatment of resistant COVID-19.   Bemnifosbuvir is an oral, direct acting...

Read More

April 25, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 68
  • 69
  • 70
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy